Ocuphire Pharma Results Presentation Deck

22 PK/Safety Data Findings Favorable Safety Data for Oral APX3330 APX3330 PK/serum levels as predicted at 600 mg/day Serum levels of APX3330 are consistent with previous findings in hepatitis and oncology trials Fewer subjects lost 5 or more letters at week 24 with APX3330 compared to placebo Limited treatment related AEs (mostly mild and transient) Only rash (6% APX3330 vs 2% placebo) and pruritus (12% APX3330 vs 2% placebo) were seen more frequently in APX3330 than placebo No treatment related serious TEAES • No effect on vital signs (BP, HR) No effect on physical exam No change in liver, kidney, or heart functions No effect on IOP No effect on clinical labs ● ● ● ● ● ● ● ZETA-1 Clinical Trial (Safety Population) Ocuphire

View entire presentation